US Exchange Filings

CytoSorbents Announces $4 Million Private Placement to Repay Debt

CytoSorbents is raising about $4 million, largely to repay its Avenue loan and related charges, while issuing new shares and warrants that could dilute investors. The deal also includes participation from company directors and executives.

CytoSorbents is raising about $4 million through a private placement of common stock and pre-funded warrants, with company directors and executives also participating. The company expects to use most of the net proceeds to repay $3 million of debt to Avenue, along with related repayment charges; the balance is intended for general corporate and working-capital needs.

The financing is expected to close around November 20, subject to customary conditions. It will add shares to CytoSorbents’ capital structure, with further potential dilution from warrants issued to the placement agent.

Key details

  • Shares sold: CytoSorbents agreed to sell 556,681 common shares to investors for $4.94 each. Directors and certain executives will buy another 96,527 shares at $5.18 each, the stock’s closing bid price on November 18.

  • Pre-funded warrants: Some investors will receive pre-funded warrants instead of 151,822 common shares. Each warrant cost $4.939 and can be exercised immediately for one share at an exercise price of $0.001. Exercise is subject to limits that generally prevent a holder and its affiliates from exceeding 4.99% ownership, or a higher limit of up to 9.99% if elected.

  • Proceeds and debt repayment: Gross proceeds are expected to be about $4 million, with estimated net proceeds of about $3.5 million after fees and expenses. The company plans to use $3 million to repay outstanding principal under its Avenue loan, plus a $52,500 prepayment fee and a $270,000 final payment. The remainder is designated for general corporate and working-capital purposes.

  • Placement and advisory fees: H.C. Wainwright is the exclusive placement agent and will receive a cash fee of 6% of gross proceeds, reduced to 3% for purchases by certain existing investors and their affiliates. Wainwright will also receive warrants to buy 18,078 shares at $6.175 per share. Those warrants are immediately exercisable and expire November 19, 2031. The company also agreed to specified placement-related expenses, subject to an aggregate cap of $165,950. WBB Securities will receive a $30,000 financial-advisory fee.

Plain-English implications

The offering provides CytoSorbents with new cash while directing most of the expected net proceeds toward repaying Avenue debt and associated charges. The sale of shares and the potential exercise of the pre-funded and placement-agent warrants will increase the number of shares outstanding.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.